Becton, Dickinson and Company (NYSE:BDX) Releases FY24 Earnings Guidance

Becton, Dickinson and Company (NYSE:BDX) updated its FY24 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of $12.95-13.15 for the period, compared to the consensus estimate of $12.95. The company issued revenue guidance of ~$20.1-20.3 billion, compared to the consensus revenue estimate of $20.30 billion.

Analyst Upgrades and Downgrades

Separately, Barclays increased their price target on Becton, Dickinson and Company from $301.00 to $305.00 and gave the company an overweight rating in a report on Monday, February 5th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Becton, Dickinson and Company has an average rating of Moderate Buy and a consensus target price of $280.00.

Becton, Dickinson and Company Stock Performance

Shares of NYSE BDX traded down $5.67 during midday trading on Friday, hitting $234.68. The company’s stock had a trading volume of 1,722,353 shares, compared to its average volume of 1,291,373. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.64 and a current ratio of 1.41. Becton, Dickinson and Company has a 1-year low of $229.40 and a 1-year high of $287.32. The firm’s fifty day moving average price is $238.45 and its 200-day moving average price is $240.53. The firm has a market cap of $67.80 billion, a P/E ratio of 51.69, a P/E/G ratio of 1.93 and a beta of 0.45.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.97 by $0.20. The business had revenue of $5.05 billion for the quarter, compared to the consensus estimate of $5.04 billion. Becton, Dickinson and Company had a return on equity of 13.90% and a net margin of 6.76%. The business’s revenue was up 4.6% on a year-over-year basis. During the same quarter last year, the business posted $2.86 EPS. On average, sell-side analysts forecast that Becton, Dickinson and Company will post 13.04 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 28th. Investors of record on Monday, June 10th will be issued a $0.95 dividend. This represents a $3.80 dividend on an annualized basis and a yield of 1.62%. The ex-dividend date is Monday, June 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 83.70%.

Insiders Place Their Bets

In related news, SVP Thomas J. Spoerel sold 282 shares of the company’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $238.29, for a total value of $67,197.78. Following the completion of the sale, the senior vice president now owns 2,276 shares of the company’s stock, valued at $542,348.04. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, SVP Thomas J. Spoerel sold 282 shares of the business’s stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $238.29, for a total transaction of $67,197.78. Following the sale, the senior vice president now owns 2,276 shares of the company’s stock, valued at $542,348.04. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Michael David Garrison sold 1,715 shares of the stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total value of $399,269.15. Following the transaction, the executive vice president now directly owns 5,381 shares of the company’s stock, valued at $1,252,750.61. The disclosure for this sale can be found here. 0.31% of the stock is currently owned by insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.